Optibiotix Health Share Discussion Threads

[someuwin] 21/3/2017 12:16

Going to get very exciting now!

[elrico] 21/3/2017 12:13

I believe it is a 1-1 basis, but this has NOT been officially announced. However, the source for this is share price As we all know, the source has been wrong quite few times where OPTI is concerned, usually timing related, to be fair.

[rollthedice] 21/3/2017 12:13

Why would PIs get any shares if Optibiotix holds a majority stake in Skinbiotix? Value of subsidiary will ultimately reflect in OPTI share price Suspect holders may be given an opportunity to subscribe in any planned IPO fundraise but that'll be about it.

[rafboy] 21/3/2017 12:09

We own shares now and I hope we will be given the same holding in the new division. That is to say if you now hold 10000 shares in Opti then you may well receive the same amount in any new division on demerger. I would hope that is how it pans out but who knows.

[someuwin] 21/3/2017 12:08

RNS Number : 0846AOptiBiotix Health PLC21 March 2017OptiBiotix Health plc("OptiBiotix" or the "Company")Intention to float SkinBiotherapeuticsOptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that its majority owned subsidiary, SkinBioTherapeutics (formerly SkinBiotix), intends to seek Admission to AIM with an associated institutional and private client investment manager fundraising. A Schedule One announcement in relation to the proposed Admission was issued by the London Stock Exchange earlier today.On 5 July 2016, OptiBiotix announced its strategy to form separate divisions, each containing its own technology platform, IP portfolio, and specialised teams, which could in due course become separate legal entities with the potential for a separate public listing. On 5 October 2016, Martin Hunt was appointed as Non Executive Chairman of SkinBiotherapeutics. On 20 October 2016, OptiBiotix announced that it had invested a further GBP400,000 into SkinBiotherapeutics via a Convertible Loan Agreement to build the team, IP, and research & development programmes to progress towards an Initial Public Offering. OptiBiotix's convertible loan will be converted into Ordinary Shares in SkinBioTherapeutics on Admission.OptiBiotix's strategy is based on its belief that the diversity of IP and commercial relationships across its four divisions reduces shareholder risk whilst offering multiple opportunities for value enhancement.The planned Admission of SkinBioTherapeutics brings in non dilutive funding and creates the opportunity to drive the development and commercialisation of its SkinBiotix(R) technology platform to address large scale global markets in skin health including Cosmetic Skin Care ($121bn); Health Care Acquired Infections ($82bn); and Eczema ($3.8bn).Stephen O'Hara, CEO of OptiBiotix, commented: "The rapid development and growing awareness in the microbiome have been matched by OptiBiotix's progress in a number of diverse areas of key scientific and commercial interest. OptiBiotix's skin division has built its own IP, team, and development programmes to a point where the Board believe the scale of the opportunities offered by its SkinBiotix's(R) technology in the biotherapeutic space may be best realised by separate listing. As a majority shareholder in SkinBioTherapeutics, OptiBiotix's Board believe this provides the necessary resources to grow SkinBiotherapeutics and create the potential for substantial future value enhancement."

[loungeact] 21/3/2017 12:03

Has anyone here held shares in a company involved in a spin-off before? Obviously not all spin-offs are the same, but I was curious if there was any idea as to how many shares in Skin current holders could be entitled to etc? Or perhaps if SOH had given any indication before. I think I remember the word 'proportional' in a previous interview.

[siennadelekat21] 21/3/2017 12:03

Wow.... I guess all the silence recently around skin didn't mean nothing was happening! : )CheersSienna

[mirabeau] 21/3/2017 12:01

RNS

ps not holding but watching with interest

GL

[rafboy] 21/3/2017 11:59

I suspect we may see further buying on this news.

[rafboy] 21/3/2017 11:57

Blimey, didn't see that coming so quickly. However, very good news for all shareholders.

[someuwin] 21/3/2017 11:45

Not much time left to add to OPTI holdings in order to maximise any distribution of SkinBioTherapeutics shares / warrants. imo.

[riskybusiness1] 21/3/2017 11:42

Schedule 1 is the 10 day notice to the market for the intent to list. Looks like skin is happening fast! Very big news

[someuwin] 21/3/2017 11:42

RNS Number : 0751A

AIM

21 March 2017

ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT
PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2
OF THE AIM RULES FOR COMPANIES ("AIM RULES")
----------------------------------------------------------

COMPANY NAME:
----------------------------------------------------------

SkinBioTherapeutics plc (the "Company")
----------------------------------------------------------
COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT,
COMPANY TRADING ADDRESS (INCLUDING POSTCODES)
:
----------------------------------------------------------

Registered/Trading Address:

15 Silk House
Park Green
Macclesfield
England
SK11 7QJ
----------------------------------------------------------
COUNTRY OF INCORPORATION:
----------------------------------------------------------

Incorporated in England and Wales with registered
number 09632164.
----------------------------------------------------------
COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION
REQUIRED BY AIM RULE 26:
----------------------------------------------------------
www.skinbiotherapeutics.com
----------------------------------------------------------
COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF
OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY,
DETAILS OF ITS INVESTING POLICY). IF THE ADMISSION
IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER
UNDER RULE 14, THIS SHOULD BE STATED:
----------------------------------------------------------

The Company, based in the UK, has acquired and
subsequently further developed technology and
intellectual property comprising 18 patent applications
founded on scientific evidence and proof of
principle studies. The studies indicate that
certain molecules found in the human microbiota
can be used to protect, manage and restore the
skin.

The Company has identified a range of potential
applications for its technology, and is looking
to demonstrate viability for these applications
through continued development and human studies
in order to gain access to a range of markets.

The Company's current priority is to focus on
the preparation of a cosmetic formulation for
human studies. Following the successful completion
of these studies, SkinBioTherapeutics will seek
to enter into licensing agreements and partnerships
with established companies that have specialist
skin divisions to take products to market. The
Company then intends to subsequently develop
and validate dermatological applications for
its products in the consumer, health and well-being
sectors.
----------------------------------------------------------
DETAILS OF SECURITIES TO BE ADMITTED INCLUDING
ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES
(i.e. where known, number and type of shares,
nominal value and issue price to which it seeks
admission and the number and type to be held
as treasury shares):
----------------------------------------------------------

Number of ordinary shares of 1 pence each ("Ordinary
Shares") to be admitted to trading: TBC
There are no restrictions as to transferability
of the Ordinary Shares.
No Ordinary Shares will be held in treasury
on Admission.
----------------------------------------------------------
CAPITAL TO BE RAISED ON ADMISSION (IF APPLICABLE)
AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION:
----------------------------------------------------------

Capital to be raised on admission: TBC

Anticipated market capitalisation on Admission:
TBC
----------------------------------------------------------
PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS
AT ADMISSION:
----------------------------------------------------------

TBC
----------------------------------------------------------
DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM
TO WHICH THE AIM COMPANY HAS APPLIED OR AGREED
TO HAVE ANY OF ITS SECURITIES (INCLUDING ITS
AIM SECURITIES) ADMITTED OR TRADED:
----------------------------------------------------------

None
----------------------------------------------------------
FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED
DIRECTORS (underlining the first name by which
each is known or including any other name by
which each is known):
----------------------------------------------------------

Martin Braddock Hunt - Non-Executive Chairman

Dr. Catherine Anne O'Neill - Chief Executive
Officer

Douglas John Quinn - Chief Financial Officer

Dr. Catherine Denise Prescott - Non-Executive
Director

Stephen Patrick O'Hara - Non-Executive Director
----------------------------------------------------------
FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS
EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE
CAPITAL, BEFORE AND AFTER ADMISSION (underlining
the first name by which each is known or including
any other name by which each is known):
----------------------------------------------------------

Shareholder % Holding pre % Holding post
Admission Admission
------------------ -------------- ---------------
OptiBiotix Health 72.5% TBC
plc
------------------ -------------- ---------------
University of 12.4% TBC
Manchester
------------------ -------------- ---------------
Dr. Catherine 7.6% TBC
O'Neill
------------------ -------------- ---------------
Dr. Andrew McBain 7.6% TBC
------------------ -------------- ---------------
----------------------------------------------------------
NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE
WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:
----------------------------------------------------------

None
----------------------------------------------------------
(i) ANTICIPATED ACCOUNTING REFERENCE DATE
(ii) DATE TO WHICH THE MAIN FINANCIAL INFORMATION
IN THE ADMISSION DOCUMENT HAS BEEN PREPARED
(this may be represented by unaudited interim
financial information)
(iii) DATES BY WHICH IT MUST PUBLISH ITS FIRST
THREE REPORTS PURSUANT TO AIM RULES 18 AND 19:
----------------------------------------------------------
(i) 30 June

(ii) 31 December 2016 (Audited interim financial
information)

(iii) 31 December 2017 - annual report for the
year ended 30 June 2017

31 March 2018 - half year report for the six
months to 31 December 2017

31 December 2018 - annual report for the year
ended 30 June 2018
----------------------------------------------------------
EXPECTED ADMISSION DATE:
----------------------------------------------------------

5 April 2017
----------------------------------------------------------
NAME AND ADDRESS OF NOMINATED ADVISER:
----------------------------------------------------------

Cairn Financial Advisers LLP
Cheyne House
Crown Court
62-63 Cheapside
EC2V 6AX
----------------------------------------------------------
NAME AND ADDRESS OF BROKER:
----------------------------------------------------------

Turner Pope Investments (TPI) Ltd
1st Floor
5 Old Bailey
London
EC4M 7BA
United Kingdom
----------------------------------------------------------
OTHER THAN IN THE CASE OF A QUOTED APPLICANT,
DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS)
THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM,
WITH A STATEMENT THAT THIS WILL CONTAIN FULL
DETAILS ABOUT THE APPLICANT AND THE ADMISSION
OF ITS SECURITIES:
----------------------------------------------------------

Cairn Financial Advisers LLP
Cheyne House
Crown Court
62-63 Cheapside
EC2V 6AX
----------------------------------------------------------
DATE OF NOTIFICATION:
----------------------------------------------------------

21 March 2017
----------------------------------------------------------
NEW/ UPDATE:
----------------------------------------------------------

New
----------------------------------------------------------


This information is provided by RNS

[nashwan123] 21/3/2017 11:40

Andyh

PAGE NOT FOUND

[someuwin] 21/3/2017 11:38

Things happening fast now.

[someuwin] 21/3/2017 11:38

EXPECTED ADMISSION DATE:
----------------------------------------------------------

5 April 2017


Really? That soon?

[daniel levi bmd] 21/3/2017 11:35

fyi

The Runcorn Troll, 'NO SHOW' Doc Holiday a.k.a Michael Whitlow Crumbles!

Dan
x

[andyhayward1990] 21/3/2017 11:34

Link to above:

londonstockexchange.com/exchange/news/market-news/market-news-detail/other/13165932.html

[mirabeau] 21/3/2017 11:24

AIM -
Schedule One - SkinBioTherapeutics Plc
Released 11:15 21-Mar-2017

Is this something to do with this company?

Main shareholder is Optibiotix Health PLC

[tightfist] 21/3/2017 10:41

Highest Close appears to be 97p (12/11/15), Intraday OPTI hit 101.5p.We shall see; confident of that IMO!

[judijudi] 21/3/2017 10:25

I think if you look back there was resistance around the £1 mark
And when we get there this next time, I would expect the same again

[tightfist] 21/3/2017 10:19

Erico,Yup, 90p has resisted us twice in the last 15 months. The good news is that is North of 90p there is no round numbers resistance....... :-)Incidentally, I see a new lower priced GoFigure stockist has appeared on Amazon - "Sports Inside"

[elrico] 21/3/2017 10:09

Its not rocket or even TA science. Round numbers attract sellers. I predict sellers at 90p next ;-)